ARKAY Therapeutics
ARKAY Therapeutics is dedicated to developing and commercializing innovative medicines for Type 2 diabetes, focusing on a 'Beta-cell-centric' platform to address the unmet medical needs in diabetes treatment. Their mission is to change the current disease trajectory by targeting inflammation and beta cell dysfunction, aiming to restore beta cell function and prevent disease progression.
Industries
Nr. of Employees
small (1-50)
ARKAY Therapeutics
Windsor, New Jersey, United States, North America
Products
Beta-cell-centric combination therapeutic for Type 2 diabetes (clinical-stage)
A combination drug product designed to target inflammatory and metabolic pathways to preserve pancreatic beta-cell function, reduce insulin resistance, and improve long-term glycemic control; evaluated in preclinical DIO rodent models and progressed to an IND-approved human clinical study.
Precision combination formulation platform (ParamAushadam)
A formulation technology platform for combining therapeutically efficacious doses of multiple drugs with predetermined modified-release kinetics to achieve optimized therapeutic synergies while minimizing adverse interactions.
TriGlytza™
An innovative, patient-centric drug designed to treat Type 2 diabetes by targeting multidimensional pathophysiology, preventing beta cell failure, decreasing insulin resistance, and preventing failure of Metformin treatment. It is custom-designed and formulated to address comorbidities such as high blood pressure and arthritis in Type 2 diabetes patients.
Beta-cell-centric combination therapeutic for Type 2 diabetes (clinical-stage)
A combination drug product designed to target inflammatory and metabolic pathways to preserve pancreatic beta-cell function, reduce insulin resistance, and improve long-term glycemic control; evaluated in preclinical DIO rodent models and progressed to an IND-approved human clinical study.
Precision combination formulation platform (ParamAushadam)
A formulation technology platform for combining therapeutically efficacious doses of multiple drugs with predetermined modified-release kinetics to achieve optimized therapeutic synergies while minimizing adverse interactions.
TriGlytza™
An innovative, patient-centric drug designed to treat Type 2 diabetes by targeting multidimensional pathophysiology, preventing beta cell failure, decreasing insulin resistance, and preventing failure of Metformin treatment. It is custom-designed and formulated to address comorbidities such as high blood pressure and arthritis in Type 2 diabetes patients.
Services
Consulting and advisory support from experienced translational, clinical development, regulatory, and intellectual property advisors to support asset advancement or licensing.
Program management and coordination with contract research organizations for formulation development, manufacturing of clinical supplies, trial monitoring, and clinical data management.
Consulting and advisory support from experienced translational, clinical development, regulatory, and intellectual property advisors to support asset advancement or licensing.
Program management and coordination with contract research organizations for formulation development, manufacturing of clinical supplies, trial monitoring, and clinical data management.
Expertise Areas
- Clinical trial management and early-stage clinical development
- Formulation development and controlled-release combination products
- Preclinical pharmacology using diet-induced obesity animal models
- Translational beta-cell biology and inflammation-focused therapeutics
Key Technologies
- Controlled-release/modified-release formulation
- Combination drug product formulation
- Diet-induced obesity (DIO) rodent models
- Immunofluorescence imaging and histology